Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 13/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808810 | 0.90 | F2RL3 (0.43) | F2RL3ELANEF2PLAURXFP1 | |
| SCHEMBL14884875 | 0.80 | F2RL3 (0.62) | F2RL3ELANEF2PLAUMEN1 | |
| SCHEMBL3804459 | 0.79 | PTGER4 (0.41) | MEN1KMT2AKDM4EHSD17B10 | |
| SCHEMBL3806317 | 0.74 | F2RL3 (0.48) | F2RL3ELANEF2PLAURXFP1 | |
| SCHEMBL3785436 | 0.73 | CHRM1 (0.53) | F2RL3ELANEF2PLAUMEN1 | |
| SCHEMBL14875338 | 0.72 | F2RL3 (0.44) | F2RL3ELANEF2PLAURXFP1 | |
| SCHEMBL615728 | 0.72 | ELANE (0.42) | F2RL3ELANEF2PLAUMEN1 | |
| SCHEMBL615481 | 0.72 | KMT2A (0.42) | F2RL3ELANEMEN1KMT2AGABRA1 | |
| SCHEMBL25966954 | 0.71 | ELANE (0.65) | F2RL3ELANEF2PLAUMEN1 | |
| SCHEMBL3804654 | 0.71 | GABRA1 (0.42) | F2RL3ELANEMEN1KMT2AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398324-B1 | PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8653079-B2 | Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8486946-B2 | Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301167-A1 | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | F2RL3 396/4885ELANE 3740/4885F2 2368/4885 |
| US-20130102599-A1 | PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CNR1, MTNR1A | F2RL3 396/4885ELANE 3740/4885F2 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.